Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

Recruiting

Phase 3

Study of ALXN2220 Versus Placebo in Adults With ATTR-CMStudy of ALXN2220 Versus Placebo in Adults With ATTR-CM

Sponsor:

Alexion Pharmaceuticals, Inc.

Code:

NCT06183931

Conditions

Transthyretin Amyloid Cardiomyopathy

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

ALXN2220

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by Alexion Pharmaceuticals, Inc. on 2025-03-25.